Parkinson’s disease affects over one million people in the United States. Parkinson’s disease is a progressive disease that results from the loss of dopamine producing neurons and leads to tremor, rigidity and uncontrollable movements. The majority of patients will end up on levodopa as a main therapeutic intervention to address these symptoms. Chronic levodopa use can lead to irregular movements, dyskinesias, as well as a frozen state or “OFF” episodes.
Our INP103 program is designed to address these “OFF” episodes by providing levodopa via our POD™ technology. Consistent and predictable intranasal delivery of levodopa, by either the patient or a caregiver, can get Parkinson’s patients moving again so they can improve their activities of daily living. The INP103 program will begin clinical trials and report topline clinical results in 2018.